國家衛生研究院 NHRI:Item 3990099045/9222
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 910548      在线人数 : 831
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/9222


    题名: A phase II study of sequential capecitabine plus oxaliplatin (XELOX) followed by docetaxel plus capecitabine (TX) in patients with unresectable gastric adenocarcinoma: The TCOG T3211 trial
    作者: Chen, MH;Lin, JS;Hsiao, CF;Shan, YS;Chen, YC;Chen, LT;Liu, TW;Li, CP;Chao, Y
    贡献者: Division of Clinical Trial Statistics;National Institute of Cancer Research
    摘要: Background: Fluorouracil and platinum can be considered a standard option for advanced gastric cancer (AGC). Docetaxel is also an effective agent with no cross-resistance with fluorouracil and platinum. Concomitant combination of docetxel with fluorouracil and platinum had been explored, but demonstrated intolerable toxicities. A different way to include all active agents in first-line treatment of gastric adenocarcinoma may be to use them sequentially. We aimed to evaluate the activity and the safety profile of sequential chemotherapy with capecitabine plus oxaliplatin followed by docetaxel plus capecitabine in the first-line treatment of AGC. Methods: We conducted a phase II study of first-line sequential chemotherapy in AGC. Treatment consisted of 6 cycles of capecitabine plus oxaliplatin (XELOX, Capecitabine 1000 mg/m2 bid on day 1-10 and Oxaliplatin 85 mg/m2 on day 1, Q2W) followed by 4 cycles of docetaxel plus capecitabine (TX, Docetaxel 30 mg/m2 on D1 and D8, Capecitabine 825 mg/m2 bid on day 1-14, Q3W). Primary end-point was the objective response rate. Results: Fifty-one patients were enrolled: median age 63 years; Male/Female: 37/14. Main grade 3-4 toxicities were ANC decreased (25.5%), diarrhea (11.8%), hand-foot syndrome (15.7%) and anemia (11.8%). The objective response rate was 56.9%. Median PFS and OS were 8.6 and 10.8 months, respectively. Five patients (9.8%) received surgery after chemotherapy and four were still on disease-free status. Conclusions: This sequential treatment demonstrated feasibility with a favorable safety profile and produced encouraging results in terms of activity and efficacy.
    日期: 2015-05
    關聯: Journal of Clinical Oncology. 2015 May;33(15, Suppl.):4024.
    Link to: http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/4024
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0732-183X&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000358036900863
    显示于类别:[蕭金福] 會議論文/會議摘要
    [陳立宗] 會議論文/會議摘要
    [劉滄梧] 會議論文/會議摘要

    文件中的档案:

    档案 描述 大小格式浏览次数
    ISI000358036900863.pdf49KbAdobe PDF546检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈